摘要
Abstract
Objective:To investigate the effect of Edaravone and Dexborneol combined with Butylphthalein on clinical effect and S100β protein level in patients with acute ischemic stroke.Method:A total of 104 patients with acute ischemic stroke admitted to Jining Third People's Hospital from January 2021 to January 2023 were selected and divided into study group(n=52)and control group(n=52)by random number table method.The control group was treated with Butylphthalein,and the study group was treated with Edaravone and Dexborneol combined with Butylphthalein.The clinical efficacy,neurological function,daily living ability,S100β protein level and adverse reactions were compared between the two groups.Result:The total effective rate of the study group(94.23%)was higher than that of the control group(78.85%),the difference was statistically significant(P<0.05).After treatment,the Barthel index scores of both groups were increased,and the national institutes of health stroke scale(NIHSS)scores were decreased,the Barthel index score of the study group was higher than that of the control group,and the NIHSS score was lower than that of the control group,the differences were statistically significant(P<0.05).After treatment,S100β protein levels were decreased in both groups,and the level in the study group was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(7.69%)and the control group(13.46%)(P>0.05).Conclusion:Edaravone and Dexborneol combined with Butylphthalein in the treatment of acute ischemic stroke can improve clinical effect,improve nerve function and S100β protein level,promote the improvement of daily living ability,and avoid aggravating adverse reactions.关键词
依达拉奉右莰醇/丁苯酞/急性缺血性脑卒中/神经功能/S100β蛋白Key words
Edaravone and Dexborneol/Butylphthalide/Acute ischemic stroke/Neurological function/S100β protein
